FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene

[FDA]

FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based o


Baca selengkapnya di : http://www.fda.gov...